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arson P, Anand I, O’Connor C, et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing,
nd Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005;46:2329 –34.
ne of the author’s name was printed incorrectly. Jalil Ghali, MD, FACC should have been Jalal Ghali, MD, FACC. The
uthors apologize for this error.
doi:10.1016/j.jacc.2008.04.010
cCullough PA. Contrast-Induced Acute Kidney Injury. J Am Coll Cardiol 2008;51:1419 –28.
n page 1425, paragraph 2 under the Volume Expansion heading, the correct statement shoud read: “1.0 to 1.5 ml/kg/h
f intravenous fluid” instead of “1.0 to 1.5 ml/kg/min of intravenous fluid.” The author apologizes for this error.
doi:10.1016/j.jacc.2008.04.007
ozlik-Feldmann R, Lang N, Aumann R, et al. Patch closure of muscular ventricular septal defects with a new hybrid
herapy in a pig model. J Am Coll Cardiol 2008;51:1597– 603.
n this article, the name of one of the authors was misspelled. Please note the correct spelling: Nikolay V. Vasilyev, MD.
doi:10.1016/j.jacc.2008.04.014
hite HD, Chew DP, Hoekstra JW, et al. Safety and efficacy of switching from either unfractionated heparin or
noxaparin to bivalirudin in patients with non–ST-segment elevation acute coronary syndromes managed with an
nvasive strategy: Results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Am Coll Cardiol 2008;51:1734 – 41.
n this article, the disclosures for Dr. Chadwick D. Miller were omitted. The full disclosures are below:
Dr. Miller is receiving or has received research support from Schering-Plough Research, Biosite, Millennium/Schering-
lough Research, Heartscape Inc., and Johnson & Johnson/Scios, Inc.; has received lecture fees from Genentech; and has
erved as a consultant to The Medicines Company, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, and
olecular Insight.
doi:10.1016/j.jacc.2008.04.015
